Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS-mutated”

130 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 130 results

Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Looking for participantsNCT06763029
What this trial is testing

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Fudan University 36
Testing effectiveness (Phase 2)Study completedNCT00655161
What this trial is testing

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Who this might be right for
NSCLC
GlobeImmune 24
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06936527
What this trial is testing

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Who this might be right for
Colorectal CancerMetastatic Colorectal Cancer With RAS Mutation
NovaOnco Therapeutics Co., Ltd. 102
Large-scale testing (Phase 3)Looking for participantsNCT06566755
What this trial is testing

Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

Who this might be right for
Colorectal Cancer
Caigang Liu 30
Large-scale testing (Phase 3)Study completedNCT02818725
What this trial is testing

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

Who this might be right for
Infiltrating Urothelial CarcinomaKRAS Gene Mutation
UNICANCER 133
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07678593
What this trial is testing

GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Who this might be right for
Advanced Solid Tumors CancerPancreatic Ductal AdenocarcinomaRAS Mutation
Genfleet Therapeutics (Shanghai) Inc. 222
Testing effectiveness (Phase 2)UnknownNCT05640726
What this trial is testing

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Who this might be right for
Rectal Cancer
Fujian Cancer Hospital 30
Early research (Phase 1)Ended earlyNCT05831995
What this trial is testing

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Who this might be right for
Advanced Solid TumorRAS MutationRAF Mutation+1 more
ABM Therapeutics Corporation 12
Testing effectiveness (Phase 2)UnknownNCT05970302
What this trial is testing

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Who this might be right for
TislelizumabBevacizumabOxaliplatin+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 52
Early research (Phase 1)Not Yet RecruitingNCT07686445
What this trial is testing

AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

Who this might be right for
Solid Tumor (Phase I)RAS MutationCEACAM5
Adlai Nortye Biopharma Co., Ltd. 228
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Early research (Phase 1)Study completedNCT03597581
What this trial is testing

RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Who this might be right for
Gastrointestinal CancerGastrointestinal NeoplasmsColorectal Cancer+7 more
Inspirna, Inc. 89
Not applicableUnknownNCT02502656
What this trial is testing

RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Association des Gastroentérologues Oncologues 425
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Large-scale testing (Phase 3)Active Not RecruitingNCT06625320
What this trial is testing

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Looking for participantsNCT05727163
What this trial is testing

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 194
Testing effectiveness (Phase 2)Looking for participantsNCT06218810
What this trial is testing

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal CancerMicrosatellite Stable Colorectal CarcinomaRAS Mutation+1 more
Fudan University 53
Testing effectiveness (Phase 2)Ended earlyNCT02175654
What this trial is testing

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

Who this might be right for
Colorectal NeoplasmsMetastatic Disease
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 15
Next Page